Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pharmaceutical Executive Magazine's 2013 Drug "Brand of the Year" Awarded to Leading Merck Diabetes Drug Januvia



 Pharmaceutical Executive Magazine's 2013 Drug "Brand of the Year" Awarded to
                     Leading Merck Diabetes Drug Januvia

PR Newswire

NEW YORK, March 26, 2013

NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly
magazine and daily online publication of record on analytics, trends and
personalities in the biopharmaceutical industry worldwide, announced today the
choice for its 2013's drug Brand of the Year: Merck's Januvia [sitagliptin], a
first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type
II] diabetes.    

Brand of the Year is an independent, non-promotional designation, selected
annually since 1998 by the publication's editorial staff and expert Advisory
Board. It seeks to recognize FDA-authorized prescription medicines with a
track record of clinical innovation as well as consistent, real-world
performance and appeal to patients. It must also demonstrate novelty in the
developer's approach to brand-building and market awareness activities.

Januvia was developed and has been marketed by Merck since 2006, and, along
with its sister drug Janumet, is now the biggest-selling therapeutic franchise
in the company's 122 year history.  "We are pleased to devote our March cover
to this important medicine, not only because of its breakthrough status in
regulating blood sugar among Type II patients, with fewer side effects, but
also for the higher profile it has given to a debilitating chronic condition
that contributed to the deaths of more than 4.6 million people worldwide in
2011," said Pharm Exec Editor-in-Chief William Looney.

The story, authored by Senior Editor Ben Comer, features interviews and
backgrounders with several top Merck executives, representatives of the
original product launch team, patient groups and independent medical experts,
all of whom point to the need for further progress by the pharmaceutical
industry in combating persistent challenges in managing this growing illness –
despite the success of clinically effective medicines like Januvia, half of
all diabetes patients still fail to complete the drug therapy recommended by
their physician.  

Full text of the story as well as a video display summary is available on the
Pharmaceutical Executive web site, at www.pharmexec.com.  Editorial staff are
also available for comment and interviews:  please contact Email.

Pharmaceutical Executive probes the interface of business practice and public
policy for the global biopharmaceutical, vaccine and medical device
industries.  PharmExec's editorial remit covers strategy in the "c-suite" as
well as regulatory and legal actions; sales promotion and marketing; R&D;
finance; human resources; pricing and market access; and new technology.
 Published by Advanstar Communications, PharmExec's editorial content is
available in the award-winning monthly print edition as well as in a number of
digital platforms.  

Media Contact: 
William Looney 
212-951-6735

This press release was issued through eReleases® Press Release Distribution.
For more information, visit http://www.ereleases.com.

SOURCE Pharmaceutical Executive

Website: http://www.pharmexec.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement